| 1 |
Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2016 annual data report: kidney[J]. Am J Transplant, 2018,18(Suppl 1):18-113.
|
| 2 |
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J]. Clin Pharmacokinet, 2004,43(10):623-653.
|
| 3 |
Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose[J]. J Clin Pharmacol, 2001,41(3):289-297.
|
| 4 |
Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects[J]. J Clin Pharmacol, 2001,41(2):176-182.
|
| 5 |
Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management[J]. Transplant Rev (Orlando), 2015,29(2):78-84.
|
| 6 |
Pashaee N, Bouamar R, Hesselink DA, et al. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance[J]. Ther Drug Monit, 2011,33(3):369-371.
|
| 7 |
Spierings N, Holt DW, MacPhee IA. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients[J]. Ther Drug Monit, 2013,35(3):328-331.
|
| 8 |
Yong CJ, Jung LY, Bok JS, et al. CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study[J]. Ther Drug Monit, 2010,32(1):67-72.
|
| 9 |
Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations[J]. Expert Opin Drug Metab Toxicol, 2016,12(5):555-565.
|
| 10 |
Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation[J]. Nephrol Dial Transplant, 2010,25(8): 2757-2763.
|
| 11 |
Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation[J]. Ther Drug Monit, 2012,34(6):680-685.
|
| 12 |
Sapir-Pichhadze R, Wang Y, Famure O, et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure[J]. Kidney Int, 2014,85(6):1404-1411.
|
| 13 |
Shuker N, Shuker L, van Rosmalen J, et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation[J]. Transpl Int, 2016,29(11):1158-1167.
|
| 14 |
Tullius SG, Tran H, Guleria I, et al. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome[J]. Ann Surg, 2010,252(4):662-674.
|
| 15 |
Shi YY, Hesselink DA, van Gelder T. Pharmacokinetics and pharmocodynamics of immunosuppressive drugs in elderly kidney transplant recipients[J]. Transplant Rev, 2015,29(4):224-230.
|
| 16 |
Salvadori M, Rosati A, Bock A, et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant[J]. Transplantation, 2006,81(2):202-206.
|
| 17 |
Lieber SR, Helcer J, Shemesh E. Monitoring drug adherence[J]. Transplant Rev(Orlando), 2015,29(2):73-77.
|
| 18 |
Takahashi K, Abe R, Usuki S, et al. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan[J]. Transplant Proc, 2014,46(2):406-410.
|
| 19 |
Stiff F, Stolk LML, Undre N, et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation[J]. Transplantation, 2014,97(7):775-780.
|
| 20 |
Shuker N, Cadogan M, van Gelder T, et al. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure[J]. Ther Drug Monit, 2015,37(2):262-269.
|